PODD— AI Stock Forecast & Price Targets
Published 7/10/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live PODD price forecast →
PODD is a genuinely high-quality diabetes device franchise (71% gross margins, 23% ROE, 32% TTM sales growth) that has been cut nearly in half YTD to ~$161, creating a quality-on-sale setup — but the stock remains stuck below a broken SMA200 (~35% overhead), carries fresh FDA Class I recall liability, and faces a binary Aug 5 earnings print. I recommend ACCUMULATE with disciplined sizing: this is a name to build into on weakness toward $140 support, not to chase into the print at 37x trailing P/E with sell-side targets that have consistently overshot.
Into the Aug 5 print (26 days away), the risk/reward for a fresh full-size long is poor: 37x trailing P/E, unresolved recall liability, and IV that will crush post-print. Stance is pre-earnings accumulation only, sized at 1/3 to 1/2 of a target position. Preferred entries: $150-155 (near-term VWAP zone) or $140-142 (retest of 52-week low). Invalidation: a close below $138.79 breaks the base and opens $120. Do NOT hold a swing trade through the print as your primary catalyst — either take partial profits into any run to $175-180, or hedge with a put spread. The Aug 5 report IS the invalidation event.
1-6 month view: if Aug 5 shows revenue durability (>25% Y/Y), contained warranty/recall charges, and reaffirmed FY guide, the stock has a credible path to reclaim $180-195 (nearest shelf) and potentially $220 on a multiple re-rating toward 22-24x forward EPS. Base case return from $161 to $185 is ~+15%. Catalysts: earnings print, any Omnipod 5 pediatric label expansion, further international launches, and quantification of recall costs. What would change my mind: (a) a Q2 miss with a guide cut, (b) new recall expansion or DOJ/enforcement escalation, (c) failure to hold $138 on the print — any of these push me to TRIM/HOLD.
1-3 year terminal thesis: PODD remains the dominant tubeless AID platform, and the addressable Type 1 + insulin-intensive Type 2 population globally is materially under-penetrated. If management executes on Omnipod 5 international rollout and defends the CGM-integration moat versus Tandem/Medtronic, 20%+ revenue CAGR with expanding operating leverage supports EPS in the $12-15 range by 2028, which even at a de-rated 22x multiple implies $260-330. Biggest structural risks: (1) competitive erosion from a next-gen closed-loop pump from a well-capitalized rival, (2) durable regulatory scrutiny on AID software safety post the Class I recall, (3) reimbursement pressure as AID becomes commoditized. This is a legitimate compounder trading at a legitimate discount — but the compounding thesis requires the recall/litigation to resolve without permanent brand damage.
The operating model is one of the best in medical devices: TTM revenue $2.90B with Q1'26 revenue of $761.7M (+33.9% Y/Y as noted in the snapshot), gross margin 71% (Q1 gross margin 69.5%, Q4'25 72.5%), operating margin ~16-19%, and net margin ~10-13%. ROE 23% and ROIC 13.6% confirm real economic returns rather than accounting flatter. Cash flow is high-quality: TTM operating cash flow $619M and FCF $253M, with Q1'26 OCF of $113.8M and FCF $86M despite elevated capex. Balance sheet is sound — $480M cash against $948M debt, current ratio 2.49, debt/equity 0.73, and stockholders' equity $1.30B; leverage is manageable given EBITDA of ~$600M. What's broken is the valuation math: 36.8x trailing P/E and 8.4x P/B leave little cushion if growth decelerates or the recall bites harder than expected. Forward P/E of 19.5x and PEG of 0.73 are much more defensible IF the 24.5% next-year EPS growth estimate holds — that is the crux of the debate.
The multi-timeframe picture is bearish structurally but improving tactically. On the weekly/daily chart the stock is -35% below its SMA200 and -55% from the 52-week high of $354.88, confirming a broken long-term trend; SMA20 (+3.8%) and SMA50 (+2.7%) have flattened and price is now testing the underside of nearer averages. The 1h and 4h charts show the model's forecast band leaning higher (1h forecast $187.94 vs actual $158.87; 4h $321.09) — but the daily forecast is more muted at $245 and the weekly at $285, and the model's realized 1wk directional accuracy (50% vs 83% naive baseline) means the higher-timeframe forecasts should be heavily discounted. RSI at 53 is neutral, +4.5% on the month and -22% on the quarter suggests base-building rather than a reversal. Key levels: support $138-140 (52-week low, must hold through print), resistance $180-195 (nearest failed shelf), then $220 and finally the SMA200 zone in the $240s which is the real trend-change gate. Until SMA200 is reclaimed, bounces should be treated as counter-trend.
News flow is mixed-to-negative but with pockets of operational progress. Signal: (1) the Omnipod 5 commercial launch in Spain adds another European reimbursement corridor, consistent with the international expansion thesis; (2) Citigroup raised its PT to $172 (from $165) while keeping Neutral, and Evercore cut PT to $180 from $200 keeping Outperform — sell-side is trimming but staying constructive, with the tape's $235.57 consensus target sitting ~46% above spot; (3) Zacks flagged PODD as a likely earnings beat candidate into Aug 5. Noise/negative: multiple Simply Wall St./Yahoo pieces reiterate the -47% one-year drawdown and the class-action litigation plus FDA Class I recall as unresolved overhangs. Congressional disclosures show a Senator's spouse sold two tranches ($100k-$250k each) in late April/early May — a modestly negative positioning signal but not decisive. Social sentiment skews bullish but on very low volume (n=4 tagged) — a contrarian yellow flag, not red.
- Omnipod 5 commercial launch in Spain plus Omnipod Discover data platform — adds a major EU market and layers software/data monetization on top of hardware
- Q1'26 revenue +33.9% Y/Y demonstrates the international + pharmacy-channel flywheel is still accelerating despite the recall overhang
- PEG of 0.73 and consensus 24.5% next-year EPS growth suggest operating leverage is set to inflect if margin trajectory (Q4'25 gross margin 72.5%) holds
- Analyst consensus target $235.57 with Recom 1.43 (near strong-buy) implies sell-side sees ~46% upside once recall/earnings uncertainty clears
- Potential Omnipod 5 label expansion into Type 2 insulin-intensive and pediatric segments — a materially larger TAM than current Type 1 base
- FDA Class I recall carries ongoing warranty, remediation, and class-action litigation exposure that is not yet fully quantified in guidance
- Trailing P/E of 36.8x and P/B of 8.4x leave zero cushion for a growth deceleration; the stock re-rated -47% in a year and could re-rate further
- Aug 5 earnings is a binary gap event; consensus expects a beat, so bar is elevated and disappointment risk is asymmetric
- Broken weekly trend with price -35% below SMA200 — historical pattern on this name shows bounces off support inside broken trends have repeatedly failed
- Congressional-affiliated selling in April/May and weak short-term forecast reliability (1wk directional accuracy below naive baseline) argue against chasing
- Competitive risk from Tandem Mobi, Medtronic 780G, and potential next-gen entrants pressuring the tubeless AID moat over 24-36 months
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord